Session » Vasculitis – ANCA-Associated Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0735

ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0732

Antineutrophil Cytoplasmic Antibodies and Associated Vasculitis According to Clinical Phenotypes: A Single-Center Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0730

Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes

10:30AM-12:30PM: Abstract Number: 0717

Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020

10:30AM-12:30PM: Abstract Number: 0731

Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

10:30AM-12:30PM: Abstract Number: 0715

Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited

10:30AM-12:30PM: Abstract Number: 0721

Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study

10:30AM-12:30PM: Abstract Number: 0729

Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results

10:30AM-12:30PM: Abstract Number: 0722

Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0728

Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis

10:30AM-12:30PM: Abstract Number: 0720

Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care

10:30AM-12:30PM: Abstract Number: 0718

Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic

10:30AM-12:30PM: Abstract Number: 0724

Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

10:30AM-12:30PM: Abstract Number: 0733

Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)

10:30AM-12:30PM: Abstract Number: 0734

Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 0726

Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 0716

Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)

10:30AM-12:30PM: Abstract Number: 0727

Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study

10:30AM-12:30PM: Abstract Number: 0719

Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease

10:30AM-12:30PM: Abstract Number: 0725

Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0723

Sociodemographic Factors Associated with Clinic Non-attendance and Unscheduled Emergency Care Episodes in ANCA-associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0714

Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].